Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Total Valuation
Wuxi Biologics (Cayman) has a market cap or net worth of $104.36B. The enterprise value is HK$218.55B.
Market Cap$104.36B
Enterprise ValueHK$218.55B
Share Statistics
Wuxi Biologics (Cayman) has 4,068,680,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,068,680,700
Owned by Insiders―
Owned by Institutions0.02%
Financial Efficiency
Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 7.96%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.96%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee1.49M
Profits Per Employee384.45K
Employee Count12,575
Asset Turnover0.33
Inventory Turnover7.25
Valuation Ratios
The current PE Ratio of Wuxi Biologics (Cayman) is 20.06. Wuxi Biologics (Cayman)’s PEG ratio is 1.62.
PE Ratio20.06
PS Ratio0.00
PB Ratio6.29
Price to Fair Value1.61
Price to FCF-674.95
Price to Operating Cash Flow39.79
PEG Ratio1.62
Income Statement
In the last 12 months, Wuxi Biologics (Cayman) had revenue of 18.68B and earned 3.36B in profits. Earnings per share was 0.89.
Revenue18.68B
Gross Profit7.65B
Operating Income4.97B
Pretax Income4.83B
Net Income3.36B
EBITDA6.43B
Earnings Per Share (EPS)0.89
Cash Flow
In the last 12 months, operating cash flow was 5.22B and capital expenditures -3.93B, giving a free cash flow of 1.29B billion.
Operating Cash Flow5.22B
Free Cash Flow1.29B
Free Cash Flow per Share0.32
Dividends & Yields
Wuxi Biologics (Cayman) pays an annual dividend of HK$0.055, resulting in a dividend yield of ―
Dividend Per ShareHK$0.055
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.72
52-Week Price Change132.68%
50-Day Moving Average24.40
200-Day Moving Average20.19
Relative Strength Index (RSI)54.86
Average Volume (3m)43.61M
Important Dates
Wuxi Biologics (Cayman) upcoming earnings date is Aug 25, 2025, TBA (Confirmed).
Last Earnings DateMar 25, 2025
Next Earnings DateAug 25, 2025
Ex-Dividend DateNov 02, 2023
Financial Position
Wuxi Biologics (Cayman) as a current ratio of 2.73, with Debt / Equity ratio of 12.62%
Current Ratio2.73
Quick Ratio2.56
Debt to Market Cap0.04
Net Debt to EBITDA-0.52
Interest Coverage Ratio31.56
Taxes
In the past 12 months, Wuxi Biologics (Cayman) has paid 889.03M in taxes.
Income Tax889.03M
Effective Tax Rate0.18
Enterprise Valuation
Wuxi Biologics (Cayman) EV to EBITDA ratio is 9.95, with an EV/FCF ratio of 49.69.
EV to Sales3.43
EV to EBITDA9.95
EV to Free Cash Flow49.69
EV to Operating Cash Flow12.26
Balance Sheet
Wuxi Biologics (Cayman) has $10.71B in cash and marketable securities with ¥4.94B in debt, giving a net cash position of -$5.77B billion.
Cash & Marketable Securities$10.71B
Total Debt¥4.94B
Net Cash-$5.77B
Net Cash Per Share-$1.42
Tangible Book Value Per Share$10.66
Margins
Gross margin is 44.04%, with operating margin of 26.63%, and net profit margin of 17.97%.
Gross Margin44.04%
Operating Margin26.63%
Pretax Margin25.89%
Net Profit Margin17.97%
EBITDA Margin34.43%
EBIT Margin26.73%
Analyst Forecast
The average price target for Wuxi Biologics (Cayman) is $25.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$25.67
Price Target Upside-2.04% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast7.52%
EPS Growth Forecast-1.92%